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Introduction: Although the association between alpha 1-antitrypsin
deficiency (1ATD) carriers and lung cancer risk has been found,
the effects of 1ATD carriers and serum alpha 1-antitrypsin (1AT)
concentration on non-small cell lung cancer (NSCLC) survival
remained unclear.
Methods: Patients were selected from the Epidemiology and Ge-
netics of Lung Cancer Study at Mayo Clinic with the criteria of (1)
primary NSCLC diagnosis and (2) available 1ATD carrier status
tested by isoelectric focusing serum 1AT concentration by immu-
nonephelometry. The effects of carrier status and serum 1AT
concentration on survival were evaluated by Cox proportional haz-
ards models with (1) a landmark approach, where overall survival
was defined from the time of blood draw to death from any cause
and (2) included only patients with blood draw time before initial
treatment.
Results: One thousand three hundred twenty-one patients were
included in this study, with 179 1ATD carriers and 1142 noncar-
riers. No differences in overall survival by 1ATD carrier status
were found (adjusted hazard ratio [AHR]: 0.98; 95% confidence
interval [CI]: 0.82–1.18). Nevertheless, serum 1AT concentration
was significantly associated with survival among all patients in the
landmark model (AHR per 50 mg/dl increments: 1.15; 95% CI:
1.10–1.20) and among patients whose blood was drawn for serum
1AT level assessment before any treatment (AHR per 50 mg/dl
increments: 1.44; 95% CI: 1.21–1.71).
Conclusions: Being an 1ATD carrier had no significant effect on
NSCLC survival. The increased serum 1AT concentration was a
poor prognosis marker for NSCLC, regardless of carrier status.
Key Words: Alpha 1-antitrypsin, Alpha 1-antitrypsin deficiency,
Non-small cell lung cancer, Survival.
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Lung cancer has been the leading cause of cancer death forboth men and women in the United States and many
regions of the world for approximately 40 years.1 Substantial
efforts have been made to identify prognostic factors that can
be used for better disease management and improvement of
survival. To date, only a few prognostic factors such as
tumor, node, and metastasis stage have been established for
determining patient management and predicting clinical out-
come; however, they still cannot predict individuals’ progno-
sis accurately within the same stage. Clinicians and research-
ers have been prompted by this issue to contemplate whether
the aggressive nature of lung cancer is genetically predeter-
mined and whether the differences in gene expressions could
be identified as additional useful clinical outcome predictors.
Alpha 1-antitrypsin deficiency (1ATD) is one of the
most common genetic disorders affecting the white popula-
tion, especially European descendants. It is an autosomal
codominant disorder and characterized by a low serum con-
centration of alpha 1-antitrypsin (1AT).2 1AT is the main
blood-borne serine protease inhibitor of a broad range of
proteases, the primary function of which is the inhibition of
neutrophil elastase.3–7 Our previous studies have shown that
being an 1ATD carrier (i.e., heterozygous individuals who
carry one deficient allele of the SERPINA1 gene) is an
independent risk factor for lung cancer.8 The relationship
between 1ATD carrier status and lung cancer prognosis is
largely unknown. Several studies have reported that patients
with 1AT expression in their tumor cells had worse prog-
nosis than those without 1AT expression, suggesting that
1AT production in tumor cells may relate to more aggres-
sive behavior in some cancers, including lung cancer.9 Ele-
vated serum 1AT concentration has been found in patients
with lung cancer compared with people without lung can-
cer.10,11 Nevertheless, the association of serum 1AT concen-
tration with lung cancer prognosis has not been studied. The
goals of this study were to investigate whether 1ATD carrier
status and serum 1AT concentration could affect survival in
patients with non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS
Study Population and Design
This is a follow-up study of our initial report on
“Alpha1-antitrypsin deficiency carriers, tobacco smoke,
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chronic obstructive pulmonary disease, and lung cancer risk”
in 2008.8 Since 1997, patients with histologically confirmed
primary NSCLC have been recruited prospectively into the
Epidemiology and Genetics of Lung Cancer study at Mayo
Clinic. All study subjects were enrolled following a proce-
dure approved by the Mayo Clinic Institutional Review
Board.12,13 Informed consent was obtained from each subject,
and blood samples for genotyping and serum measurement
were collected after recruitment into study. Serum/plasma
samples were separated and stored at 80°C. We limited our
study samples to 1321 patients whose 1ATD carrier status
and serum 1AT concentration have been tested in our earlier
study,8 by isoelectric focusing14 and immunonephelometry,15
respectively. Of the 1321 patients, 179 were 1ATD carriers,
and 1142 were noncarriers.
Patient Follow-Up and Data Collection
After initial enrollment for study, all patients were
actively followed with subsequent 6-month and annual fol-
low-up by mailed questionnaires. Annual verification of pa-
tients’ vital status was accomplished through the use of Mayo
Clinic’s electronic medical notes and registration database,
next-of-kin reports, death certificates, and obituary docu-
ments filed in patient medical records, as well as the Mayo
Clinic Tumor Registry and Social Security Death Index
website. Full medical record abstraction was conducted to
obtain the following variables for the 1321 patients: age,
gender, race, smoking history including smoking status and
pack-years, histologic cell type, tumor, node, and metastasis
stage,16 treatment modality, blood draw time for serum 1AT
measurement, and other medical conditions.
Statistical Methods
Patient characteristics were compared between 1ATD
carriers and noncarriers using a Pearson’s 2 test for categor-
ical variables, and a Student’s t test was used for continuous
variables. Overall survival (OS) was defined as the time from
NSCLC diagnosis to death. Patients who were alive at the last
contact were censored. Univariate and multivariate Cox pro-
portional hazards (PH) models were used to evaluate the
prognostic impact on survival of all factors of interest. Fac-
tors were included in multivariate models if the p value was
less than 0.05 in the univariate analysis. Because blood draw
times for 1AT serum concentration varied from baseline to
months after diagnosis or treatment, two models were applied
to investigate the effect of 1AT serum concentration on
survival. First, a Cox PH model with a landmark approach
was used with survival time defined as time from the date of
blood draw to death. Patients who had a serum 1AT value
were included in this analysis. To eliminate the potential
confounding effect of treatment on serum 1AT concentra-
tion, a second model was performed only including those
who had their blood draw before the initiation of any treat-
ment. In this model, survival time was calculated as OS
described earlier in the text. Hazard ratios (HRs) associated
with a 50 mg/dl increase in serum 1AT are reported for a
clinically useful interpretation. All analyses were performed
with SAS software, version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics and Univariate Analysis
Data for this analysis were frozen on August 19, 2010.
Median follow-up time for the 326 patients who were alive at
the time of analysis was 8.1 years with 90% of the patients
having a follow-up time beyond 5 years. One hundred thirty-
two (74%) patients in the carrier group and 863 (76%) in the
noncarrier group had died at the time of analysis. The median
OS was 2.9 years (95% confidence interval [CI]: 2.3–4.0) in
the carriers group and 2.7 years (95% CI: 2.4–3.0) in the
noncarriers group. Among the carriers, there were 106 (59%)
MS (including subtypes MS, M1S, and M2S), 44 (25%) MZ
(including subtypes MZ, M1Z, and M2Z), and 29 (16%)
other uncommon 1ATD carriers (including M[null], MI, SZ,
etc.). For further quality control, serum 1AT values for
carriers whose 1AT concentration was more than 250 mg/dl
(n  10) and noncarriers more than 500 mg/dl (n  18) were
considered outliers (from the Mayo Clinic normal value of
100–190 mg/dl) and excluded from all analyses.
Demographic, tumor, and treatment characteristics are
listed in Table 1 by carrier status. There were no significant
differences in age, gender, race, stage, smoking status, pack-
years, cell type, and initial treatment between 1ATD carriers
and noncarriers. The median serum 1AT concentration in
carriers was 127 mg/dl (range: 56–249) compared with 178.0
mg/dl (range: 88–496) in noncarriers. There were a total of
135 patients (17 carriers and 118 noncarriers) with blood
draw before the initiation of any treatment (10% of the total
sample).
In univariate analysis, gender, stage, and cell type (p 
0.05) were all significantly associated with OS. There was a
significant association of serum 1AT with OS. Carrier sta-
tus, age, race, smoking status, and pack-years were not
significantly associated with OS (Table 2).
Multivariate Analysis
After adjusting for gender, stage, and cell type, no
survival differences by carrier status were found in NSCLC
(HR: 0.98; 95% CI, 0.82–1.18; p  0.83). A significant
association between serum 1AT concentration and OS was
observed in the Cox PH model using the landmark approach
(adjusted HR [AHR] per 50 mg/dl increments: 1.15; 95% CI:
1.10–1.20; p  0.0001) in the presence of gender, stage, cell
type, and carrier status. In the subgroup of patients who had
their blood draw before treatment, the significant association
remained, with an even bigger effect (AHR per 50 mg/dl
increments: 1.44; 95% CI: 1.21–1.71; p  0.0001). The
results are presented in Table 3.
DISCUSSION
To our best knowledge, this is the first study inves-
tigating the roles of 1ATD carriers and serum 1AT
concentration on NSCLC survival. Although no difference
on OS by carrier status was found, there were significant
survival differences by 1AT serum concentration in pa-
tients with NSCLC, regardless of carrier status. Our study
results revealed the potential prognostic role of 1AT
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concentration in NSCLC may be clinically useful to both
carriers and noncarriers.
At least 10 million Americans and 120 million people
worldwide are 1ATD carriers, who do not normally have
severe 1ATD-related diseases, and most of them are not
aware of their carrier status.17 Although there have been
multiple studies investigating the role of 1ATD carriers and
risk of developing cancer, little is known about the potential
prognostic impact of 1ATD carrier status on lung cancer
survival. In our analysis of patients with lung cancer, no
association between 1ATD carriers and survival was found.
There are several potential explanations. First, the differences
between 1ATD carriers and noncarriers may be too small to
affect the overall course of NSCLC in the current study; thus,
the subtle difference cannot be detected even though the
sample size of our study was relatively large. Second, the
malignancy may have developed mechanisms to act against
the effect of carrying an 1ATD allele. Third, being an
1ATD carrier may have no impact on NSCLC survival.
1AT is the major serine protease inhibitor in human
plasma, which is synthesized primarily in the liver and, to a
lesser extent, in peripheral blood monocytes, alveolar mac-
rophages, and epithelial cells of the bronchial and gastroin-
testinal mucosa.18–20 Researchers have been searching for a







Mean (SD) 65.7 (10.2) 65.4 (11.1)
Median (range) 67.0 (37.0–86.0) 67.0 (18.0–92.0)
Gender 0.74
Female 78 (43.6) 513 (44.9)
Male 101 (56.4) 629 (55.1)
Race 0.13
White 162 (90.5) 1067 (93.6)
Non-white 17 (9.5) 73 (6.4)
Missing 0 2
Stage 0.79
I 75 (41.9) 440 (38.5)
II 18 (10.1) 109 (9.5)
III 47 (26.3) 314 (27.5)
IV 39 (21.8) 279 (24.4)
Smoking status 0.69
Never 27 (15.2) 169 (15.2)
Former 96 (53.9) 633 (56.9)
Current 55 (30.9) 310 (27.9)
Missing 1 30
Pack-years 0.77
Never smokers 27 (15.1) 168 (14.7)
40 65 (36.3) 405 (35.5)
40 and 60 34 (19.0) 255 (22.4)
60 53 (29.6) 312 (27.4)
Missing 0 2
Histologic cell type 0.36
Adenocarcinoma 99 (55.3) 682 (59.7)
Squamous 57 (31.8) 305 (26.7)
Othersa 23 (12.8) 155 (13.6)
Initial treatment 0.33
Surgery 93 (54.7) 650 (60.0)
Radiation or chemotherapy, or both 60 (35.3) 322 (30.7)
Other or none 17 (10.0) 111 (10.3)
Missing 9 59
Serum 1AT concentration (mg/dl) 0.0001
Mean (SD) 138.6 (42.09) 199.3 (70.99)
Median (range) 127.0 (56.0–249.0) 178.0 (88.0–496.0)
Missing or outliers 10 8
a Includes large cell, not specified non-small cell lung cancer, adenosquamous carcinoma, sarcomatoid, and other mixed cell types.
1ATD, alpha 1-antitrypsin deficiency; 1AT, alpha 1-antitrypsin.
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correlation between 1AT and the process of neoplasia,
which may help in the diagnosis and the follow-up of patients
with cancer. Various studies have been performed in different
types of cancer, such as lung, liver, prostate, pancreases,
cervix, and colorectal. Several studies reported an elevation
of 1AT in patients with cancer.10,11,21–25 Additionally, mul-
tiple studies have shown some links between 1AT expres-
sion levels and cancer prognosis, but the conclusions were
inconsistent.24,26–28 What we currently know about 1AT led
us to believe that this protease inhibitor substance may play
a role in NSCLC survival. A higher 1AT concentration was
significantly associated with worse survival in patients with
NSCLC in our study. There are several possible mechanisms
to explain this finding. First, 1AT may have a function of
modulating host-immunodefence mechanisms in favor of
tumor cells, which may suppress the blastogenic or cytotoxic
reactions of lymphocytes by inhibiting T-cell-mediated cyto-
toxicity, antibody-dependent cell-mediated cytotoxicity, and
natural killer-cell activity.9 Second, the participation of 1AT
in tumoral invasiveness seems to be related to its degradation
by matrix metalloproteinase, resulting in the production of a
COOH-terminal fragment that increases tumor growth in
vivo.29 Our findings suggest that 1AT serum concentration
evaluation may be clinically useful in recognizing patients
who are more likely to develop a worse outcome in NSCLC.
Specifically, a higher serum 1AT concentration may indicate
a tendency for a worse outcome.
Our study has several significant strengths. First, the
sample size is reasonably large. Second, the disease pheno-
type (tumor characteristics) was properly defined. Detailed
epidemiological and clinical information was carefully and
completely collected, with thorough quality control proce-
dures. Third, the long follow-up time increased the statistical
power to detect the effect on survival. Nevertheless, our study
does have limitations. First, although we tried our best to get
the patients’ blood samples as soon as possible, still the
majority of blood samples could not be drawn before treat-
ment. Therefore, when the association between serum 1AT
concentration and NSCLC survival was evaluated, the date of
blood draw was used as the baseline instead of NSCLC
diagnosis to measure survival. We further examined a sub-
group of patients with blood draw before treatment, where
NSCLC diagnosis date was used as the starting point to assess
survival. The effect of serum 1AT on survival became even
bigger in these patients (AHR per 50 mg/dl increments: 1.44;
95% CI: 1.21–1.71). In this way, the association between
serum 1AT concentration and NSCLC survival was further
demonstrated with higher 1AT levels corresponding to
worse survival outcome. Second, no data were available on
some other potential prognostic factors for survival in the
database (e.g., Eastern Cooperative Oncology Group perfor-
TABLE 2. Univariate Analysis
Patient Characteristics
Unadjusted
HR (95% CI) p
Age (10-yr increase) 1.02 (0.96–1.09) 0.47
Gender
Female Reference
Male 1.19 (1.05–1.35) 0.01
Race
Non-white Reference
White 1.27 (0.98–1.65) 0.07
Stage
I Reference
II 1.94 (1.55–2.44) .0001
III 3.15 (2.67–3.71) .0001
IV 5.04 (4.25–5.96) .0001
Smoking status
Never Reference
Former 0.98 (0.82–1.18) 0.85
Current 0.90 (0.74–1.10) 0.32
Pack-years
Never smokers Reference
40 0.91 (0.75–1.10) 0.33
40 and 60 1.01 (0.82–1.24) 0.93
60 1.03 (0.84–1.26) 0.77
Histologic cell type
Other cell type Reference
Adenocarcinoma 0.67 (0.56–0.81) 0.0001




Carriers 0.93 (0.77–1.12) 0.43
Serum level of 1AT (50 unit
increase)
In all patientsb 1.13 (1.09–1.18) .0001




Other cell type includes large cell, not specified non-small cell lung cancer,
adenosquamous carcinoma, sarcomatoid, and other mixed cell types.
a N  1321, number of events  995.
b Cox proportional hazard model with landmark approach. Survival time was
calculated from the date of the blood draw to death. N 1303, number of events 982.
c N  128, number of events  110.
1ATD, alpha 1-antitrypsin deficiency; 1AT, alpha 1-antitrypsin; HR, hazard
ratio; CI, confidence interval.






Carriers 0.98 (0.82–1.18) 0.83
Serum level of 1AT (50 mg/dl
increase)
In all patientsbc 1.15 (1.11–1.21) 0.0001




a Adjusted for gender, cell type, and stage.
b Adjusted for gender, stage, cell type, and carrier status. N  128, number of
events  110.
c Cox proportional hazard model with landmark approach. Survival time was
calculated from the date of the blood draw to death. Adjusted for gender, stage, cell
type, and carrier status. N  1303, number of events  982.
1AT, alpha1-antitrypsin; 1ATD, alpha 1-antitrypsin deficiency; HR, hazard ratio;
CI, confidence interval.
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mance status and comorbidity information). Finally, there
may be multiple other genes and modulators involved in the
SERPINA1 gene mutation, expression, and serum 1AT con-
centration, which should be incorporated into future studies,
as well.
In conclusion, we did not find a significant association
between 1ATD carriers and OS in patients with NSCLC.
Nevertheless, our results indicate that 1AT serum concen-
tration may be a biologic marker of potential prognostic
significance in NSCLC, regardless of carrier status. Our
findings will add constructively to the existing body of
knowledge about the promising serum biomarkers on NSCLC
prognosis. Future studies are warranted to confirm these
findings and their clinical application values.
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